ALK and leptomeningeal metastasis: The prognosis of patients with NSCLC who develop meningeal carcinomatosis without driver oncogenes remains poor.[1,2]ALK inhibitors are an effective treatment option for patient with ALK-positive NSCLC who develop meningeal carcinomatosis.[4] However, the successful treatment of ALK-positive NSCLC with ALK-inhibitor-resistant meningeal carcinomatosis has not yet been reported in the literature.